India’s Glenmark Pharma cuts price of COVID-19 drug by 27% to N380 per tablet

Glenmark Pharmaceuticals had launched FabiFlu last month for Rs 103 per tablet.

India’s leading drug manufacturer, Glenmark Pharmaceuticals on Monday said it has cut the price of its antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19, by 27 per cent to Rs 75 or about N380 per tablet. Glenmark Pharmaceutica

```

Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```